AEON Company Profile and Key Details

AEON Biopharma, Inc. (AMEX:AEON) closed at $0.29 USD, losing -$0.07 (-18.94%) from the previous close of $0.36. The stock is currently mid-range between its 52-week high and low $0.26 and $1.45. With a market capitalization of about $3.42 million, AEON Biopharma, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.61). Key stats such as the average daily volume over the past year has been around 1.09 million shares, trading with heavier-than-usual volume. Headquartered in Newport Beach, CA, AEON Biopharma, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert Bancroft, the company employs approximately 8 people and listed since July 24, 2023. AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions.

AEON has shown sold momentum, gaining 9.04% over the past week and 9.09% over the past quarter, though year-to-date performance is up 9.09%. Short-term trend indicators are bearishly aligned (SMA20 -2.15%, SMA50 -1.63%, SMA200 24.44%). The stock’s 14-day RSI is 47.84 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.57% below its high and over 190.67% above its low. Average 10-day trading volume of 6.86 million shares is significantly above the 3-month average of 879.70 thousand, indicating heightened recent market interest.

AEON Biopharma, Inc. trades at a P/E ratio of -0.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -0.24 indicating negative book value, which may reflect financial stress. The P/FCF stands at -0.33, also above market averages.

AEON Biopharma, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$5.54. This means the shares are trading below this model’s fair value.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.20 to $7.20. The high target offers 1900.0% upside. The low target suggests 1900.0% downside. The mean target is $7.20. This offers 1900.0% upside. AEON Biopharma, Inc. earnings surprise history is a mixed track record. The quarter that ended May 14, 2026, missed forecasts by -34.09%. The prior quarter beat by 1714.63%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in November 13, 2024.

AEON Biopharma, Inc. has 26.31 million shares outstanding. The public float is 9.93 million shares, elevated short interest at 1.27% of float. This equals 177.90 thousand shares. The short ratio is 3.36 days. Institutional investors hold 23.38% of the float. Insiders own 76.68%. GLAZER CAPITAL, LLC holds 2.71 million shares, Strathspey Crown Holdings Group, LLC has 2.03 million shares and Forth Marc has 279.86 thousand shares.